Lipid-lowering agents (fibrates)
- PPAR-alpha agonists
- Lower triglycerides and raise HDL modestly
- Used mainly for severe hypertriglyceridemia
- Fenofibrate is usually easier with statins
- Gemfibrozil raises statin-myopathy risk
- Gallstones and creatinine changes can occur
Class at a glance
Clinical role
- Lower triglycerides and raise HDL modestly
- Used mainly for severe hypertriglyceridemia
Members / distinctions
- Fenofibrate is usually easier with statins
- Gallstones and creatinine changes can occur
Safety / monitoring
- Gemfibrozil raises statin-myopathy risk
Self-check
- What key adverse effect/risk occurs with Lipid-lowering agents (fibrates)?
Gemfibrozil raises statin-myopathy risk.
Drugs in this class (2)
All drug classes · Open the interactive console ↗
